Biotech Values

[genisi]

You probably refer to Actemra (Roche/Chugai), which is approved in EU and Japan and indeed is associated with death and severe side effects reported in the post marketing study in Japan. However, that doesn't kill the whole class yet because not all the anti IL-6 antibodies are the same for example: JNJ/CNTO human monoclonal antibody to IL-6, which binds the cytokine and not the receptor, like Actemra.